FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

/ashington,	D.C.	20549	

OMB	APPROVAL
CIVID	ALL INC VAL

hours per response:

OMB Number: 3235-0287 Estimated average burden

0.5

# Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

A claric Therapoutics Inc. [ACRC]	Relationship of Reporting Person(s) to Issuer Check all applicable)
VIVO VENTURES VII, LLC  ACIAITS THETAPEUTICS, INC. [ ACRS ]	Director X 10% Owner
(Last) (First) (Middle)  C/O VIVO CAPITAL  575 HIGH STREET, SUITE 201	Officer (give title Other (specify below) below)
4. If Amendment, Date of Original Filed (Month/Day/Year) 6.	Individual or Joint/Group Filing (Check Applicable ine)  Form filed by One Reporting Person  X Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (I 8)		4. Securities Ac Disposed Of (D)	quired (A (Instr. 3,	) or 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(111511.4)
Common Stock	10/13/2015		С		3,360,408 <sup>(1)</sup>	A	(2)	3,657,147	I	By Vivo Ventures Fund VII, L.P. <sup>(3)</sup>
Common Stock	10/13/2015		P		444,850	A	\$11	4,101,997	I	By Vivo Ventures Fund VII, L.P. <sup>(3)</sup>
Common Stock	10/13/2015		С		73,238 <sup>(1)</sup>	A	(2)	79,705	I	By Vivo Ventures VII Affiliates Fund, L.P. <sup>(4)</sup>
Common Stock	10/13/2015		P		9,695	A	\$11	89,400	I	By Vivo Ventures VII Affiliates Fund, L.P. <sup>(4)</sup>

#### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		Deri Seci Acq or D	umber of vative urities uired (A) isposed of Instr. 3, 4 5)	Expiration Date Securities Underlying (Month/Day/Year) Derivative Security		Derivative Security (Instr. 5)	itive derivative ity Securities	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Series A Preferred Stock	(2)	10/13/2015		С			8,467,943	(2)	(2)	Common Stock	2,454,476	\$0.00	0	I	By Vivo Ventures Fund VII, L.P. <sup>(3)</sup>
Series A Preferred Stock	(2)	10/13/2015		С			184,557	(2)	(2)	Common Stock	53,494	\$0.00	0	I	By Vivo Ventures VII Affiliates Fund, L.P. (4)
Series B Preferred Stock	(2)	10/13/2015		С			1,779,400	(2)	(2)	Common Stock	515,768	\$0.00	0	I	By Vivo Ventures Fund VII, L.P. <sup>(3)</sup>
Series B Preferred Stock	(2)	10/13/2015		С			38,782	(2)	(2)	Common Stock	11,241	\$0.00	0	I	By Vivo Ventures VII Affiliates Fund, L.P. (4)

	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		d 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Series C Preferred Stock	(2)	10/13/2015		С			1,346,068	(2)	(2)	Common Stock	390,164	\$0.00	0	I	By Vivo Ventures Fund VII, L.P. <sup>(3)</sup>
Series C Preferred Stock	(2)	10/13/2015		С			29,337	(2)	(2)	Common Stock	8,503	\$0.00	0	I	By Vivo Ventures VII Affiliates Fund, L.P. (4)

1. Name and Address of Reporting Person* <u>VIVO VENTURES VII, LLC</u>										
(Last)	(First)	(Middle)								
C/O VIVO CAPITAL										
575 HIGH STREET, SUITE 201										
(Street) PALO ALTO	CA	94301								
(City)	(State)	(Zip)								
1. Name and Address of Reporting Person* <u>Vivo Ventures Fund VII, L.P.</u>										
(Last)	(First)	(Middle)								
C/O VIVO CAPITA	ΔL									
575 HIGH STREET	C, SUITE 201									
(Street)										
PALO ALTO	CA	94301								
(City)	(State)	(Zip)								
1. Name and Address of Reporting Person* <u>Vivo Ventures VII Affiliates Fund, L.P.</u>										
(Last)	(First)	(Middle)								
C/O VIVO CAPITAL										
575 HIGH STREET, SUITE 201										
(Street)		-								
PALO ALTO	CA	94301								
(City)	(State)	(Zip)								

### Explanation of Responses:

- 1. The total represents shares received upon conversion of shares of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock.
- 2. Effective upon the closing of the issuer's initial public offering of its common stock, each share of preferred stock automatically converted into 0.289855 shares of common stock. The preferred stock had no expiration date.
- 3. Vivo Ventures VII, LLC ("VV LLC") is the general partner of Vivo Ventures Fund VII, L.P. ("VVF"), the record holder of the securities, and disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. In addition, each of Albert Cha, a director of the issuer, Frank Kung and Edgar Engleman is a managing member of VV LLC and may be deemed to share voting and dispositive power over the securities held by VVF. Each of such individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership over such securities for purposes of Section 16 or for any other purposes.
- 4. VV LLC is the general partner of Vivo Ventures VII Affiliates Fund, L.P. ("VVAF"), the record holder of the securities, and disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. In addition, each of Albert Cha, a director of the issuer, Frank Kung and Edgar Engleman is a managing member of VV LLC and may be deemed to share voting and dispositive power over the securities held by VVAF. Each of such individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

#### Remarks:

/s/ Albert Cha as a managing
member of Vivo Ventures VII,
LLC
/s/ Albert Cha as a managing
member of Vivo Ventures VII,
LLC, the general partner of Vivo
Ventures Fund VII, L.P.
/s/ Albert Cha as a managing
10/13/2015

member of Vivo Ventures VII, LLC, the general partner of Vivo Ventures VII Affiliates Fund, L.P.

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.